CNS Pharmaceuticals (CNSP) Competitors $8.25 +0.20 (+2.48%) Closing price 10/24/2025 03:51 PM EasternExtended Trading$8.29 +0.04 (+0.48%) As of 10/24/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. PCSA, HOTH, EGRX, AIMD, LIXT, FNCH, MTEX, SYBX, LEXX, and EDSAShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Heatwurx (PCSA), Hoth Therapeutics (HOTH), Eagle Pharmaceuticals (EGRX), Ainos (AIMD), Lixte Biotechnology (LIXT), Finch Therapeutics Group (FNCH), Mannatech (MTEX), Synlogic (SYBX), Lexaria Bioscience (LEXX), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors Heatwurx Hoth Therapeutics Eagle Pharmaceuticals Ainos Lixte Biotechnology Finch Therapeutics Group Mannatech Synlogic Lexaria Bioscience Edesa Biotech Heatwurx (NASDAQ:PCSA) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk. Which has more risk and volatility, PCSA or CNSP? Heatwurx has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Which has better valuation and earnings, PCSA or CNSP? Heatwurx is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$2.32-0.13CNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00 Do analysts prefer PCSA or CNSP? Heatwurx presently has a consensus price target of $1.00, indicating a potential upside of 222.37%. CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 142.42%. Given Heatwurx's higher probable upside, equities analysts clearly believe Heatwurx is more favorable than CNS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to PCSA or CNSP? In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.89 beat CNS Pharmaceuticals' score of 0.88 indicating that Heatwurx is being referred to more favorably in the media. Company Overall Sentiment Heatwurx Very Positive CNS Pharmaceuticals Positive Is PCSA or CNSP more profitable? CNS Pharmaceuticals' return on equity of -183.89% beat Heatwurx's return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -342.36% -243.48% CNS Pharmaceuticals N/A -183.89%-139.37% Do insiders & institutionals believe in PCSA or CNSP? 91.9% of Heatwurx shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 2.4% of Heatwurx shares are held by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCNS Pharmaceuticals beats Heatwurx on 7 of the 13 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.63M$3.43B$6.23B$10.66BDividend YieldN/A2.27%5.71%4.82%P/E Ratio0.0024.2730.2930.24Price / SalesN/A494.27591.44133.15Price / CashN/A45.5737.0161.44Price / Book0.1310.4012.046.60Net Income-$14.86M-$52.62M$3.32B$276.82M7 Day Performance-10.33%2.09%1.89%2.58%1 Month Performance-4.62%12.32%7.68%3.76%1 Year Performance-89.60%14.12%56.01%33.84% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.4897 of 5 stars$8.25+2.5%$20.00+142.4%-90.6%$4.63MN/A0.005News CoverageAnalyst ForecastPCSAHeatwurx3.2007 of 5 stars$0.39-11.1%$1.00+155.1%-76.1%$19.74MN/A-0.1720Positive NewsUpcoming EarningsHOTHHoth Therapeutics2.5573 of 5 stars$1.49-2.9%$4.50+203.0%+62.1%$19.69MN/A-1.394EGRXEagle Pharmaceuticals2.0698 of 5 stars$1.50-6.3%N/AN/A$19.48M$257.55M0.00100AIMDAinos1.5265 of 5 stars$3.94flatN/A+36.7%$18.79M$20K-0.7940Gap UpLIXTLixte Biotechnology0.1898 of 5 stars$4.11-5.3%N/A+170.6%$18.74MN/A-3.194Gap DownFNCHFinch Therapeutics Group1.6216 of 5 stars$11.52-5.2%N/A+0.4%$18.50MN/A-1.31190High Trading VolumeMTEXMannatech0.9972 of 5 stars$9.73-3.3%N/A+21.5%$18.49M$117.87M-4.77250Gap DownSYBXSynlogic1.7284 of 5 stars$1.56+0.4%N/A+26.1%$18.21M$10K-19.4580Gap UpLEXXLexaria Bioscience3.0441 of 5 stars$0.90-0.4%$4.00+344.9%-66.0%$17.58M$460K-1.347Positive NewsEDSAEdesa Biotech1.9861 of 5 stars$2.50-1.8%$5.00+100.4%-19.3%$17.57MN/A-1.8920News CoverageAnalyst Forecast Related Companies and Tools Related Companies PCSA Competitors HOTH Competitors EGRX Competitors AIMD Competitors LIXT Competitors FNCH Competitors MTEX Competitors SYBX Competitors LEXX Competitors EDSA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
